BioCardia (BCDA) Expected to Announce Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is expected to post its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last issued its earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.14. On average, analysts expect BioCardia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Trading Down 2.7%

NASDAQ:BCDA opened at $1.10 on Wednesday. The company has a market capitalization of $12.03 million, a P/E ratio of -0.85 and a beta of 0.56. BioCardia has a 12 month low of $1.00 and a 12 month high of $2.92. The business’s 50-day moving average is $1.20 and its 200 day moving average is $1.28.

Institutional Trading of BioCardia

A number of large investors have recently made changes to their positions in the business. Cetera Investment Advisers purchased a new stake in shares of BioCardia during the 2nd quarter valued at about $40,000. DRW Securities LLC purchased a new position in BioCardia in the fourth quarter worth about $72,000. Finally, Geode Capital Management LLC increased its stake in BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares during the last quarter. 20.57% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $25.00.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.